Methods for the treatment of renal failure

Details Methods for the treatment of renal failure Methods for the treatment of renal failure

2011-03-01

2011-03-01

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C514S001100

Reexamination Certificate

active

07897145

ABSTRACT:
The present invention relates to methods for treating renal failure. Particularly, the present invention relates to methods for treating renal failure by administering to a subject complexes that include a member of the IL-6 family linked to a soluble receptor of the member of the IL-6 family, or isolated polynucleotides encoding same, the complexes capable of activating a gp130 mediated signaling pathway, thereby treating acute or chronic renal failure.

REFERENCES:
patent: 5919763 (1999-07-01), Galun et al.
patent: WO 97/32891 (1997-09-01), None
patent: WO 99/62534 (1999-12-01), None
patent: WO 01/54706 (2001-08-01), None
patent: WO 03/029281 (2003-04-01), None
patent: WO 2005/113591 (2005-05-01), None
Saito M., et al. J. Immunol. 148(12):4066-4071, 1992.
Database WPI Week 199407 Derwent Publications Ltd., London, GB; AN 1994-053923 & JP 06009427 abstract.
Yoshino J. et al., “Leukemia inhibitory factor is involved in tubular regeneration after experimental acute renal failure”. J Am Soc Nephrol. Dec. 2003;14(12):3090-101.
Feinglass S. et al., “Treatment of lupus-induced thrombocytopenia with recombinant human interleukin-11”. Arthritis Rheum. Jan. 2001;44(1):170-5.
Reznikov L. et al., “Suppression of endotoxin-inducible cytokines in whole blood from human subjects following single dose of recombinant human interleukin-II”. Journal of Endotoxin Research 1999 5:197-204.
Fischer M. et al., “I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion”. Nat Biotechnol. Feb. 1997;15(2):142-5.
Peters M. et al., “In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6”. J Immunol. Oct. 1, 1998;161(7):3575-81.
Homsi E. et al., “Interleukin-6 stimulates tubular regeneration in rats with glycerol-induced acute renal failure”. Nephron. Sep. 2002;92(1):192-9.
Wang YD. et al., “gp130-linked signal transduction promotes the differentiation and maturation of dendritic cells”. Int Immunol. Jun. 2002;14(6):599-603.
Berns KI. et al., “Adenovirus and adeno-associated virus as vectors for gene therapy”. Ann N Y Acad Sci. Nov. 27, 1995;772:95-104.
Fink DJ. et al., “Gene transfer to neurons using herpes simplex virus-based vectors”. Annu Rev Neurosci. 1996;19:265-87.
Federoff HJ. et al., “Expression of nerve growth factor in vivo from a defective herpes simplex virus I vector prevents effects of axotomy on sympathetic ganglia”. Proc Natl Acad Sci U S A. Mar. 1, 1992;89(5):1636-40.
Liu F. et al., “Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA”. Gene Ther. Jul. 1999;6(7):1258-66.
Lemay S. et al., “Prominent and sustained up-regulation of gp130-signaling cytokines and the chemokine MIP-2 in murine renal ischemia-reperfusion injury”. Transplantation. Mar. 15, 2000;69(5):959-63.

Affiliated with

Also associated with

Rating

Methods for the treatment of renal failure does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for the treatment of renal failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of renal failure will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2697172